Headquartered in Dublin, Ireland Jazz Pharmaceuticals is a specialty biopharmaceuticals company that has undergone significant growth in recent years. Jazz Pharmaceuticals is focused upon delivering products for cataplexy, narcolepsy, oncology/leukemia, chronic pain and non-opioid schizophrenia.
The company is a fairly young company having only been established in 2003, today it employs up to 1000 employees. The company has a strong market portfolio which includes five major products –
- XYREM – indicated for narcolepsy
- ERWINAZE – medication indicated for leukemia in children
- PRIALT – Pain focused therapeutic
- FAZACLO – Pain treatment
- VERSACLOZ – Treatment for pain
Over the past few years the company recorded very successful earnings and this year they made it into the top 50 biotechnology list, which reflects that it is now competing with the big players in the industry. The company made a couple of major partnership deals that bolstered both its product portfolio and company workforce.
Jazz Pharmaceuticals operate through three different business routes; firstly it aims to nurture and grow sales of existing products and those that it has acquired through acquiring specialist companies, secondly it looks to acquire additional marketed or close to approval products and finally it pursues the development of lower risk development products.
One of the company’s biggest deals was announced back in 2011 when Jazz Pharmaceuticals, previously headquartered in the US bought Ireland based Azur Pharma, the two companies came together expecting to reach revenues of over $470million. The strategic acquisition for Jazz Pharmaceuticals meant it could benefit from the low corporate tax rate in Ireland. Since then Jazz Pharmaceuticals has made Ireland its home and this year it announced that it had commenced construction of a manufacturing and development facility in County Roscommon which is east of the company’s Dublin headquarters.
The company has also been involved with a number of other partnerships, later in 2012 after it has secured the purchase of Azur Pharma, it went onto acquire US based EUSA Pharma for $650million. EUSA at the time had 10 products one of which was Erwinaze, a very popular US marketed product that treated leukaemia in children.
Further funnelling its therapeutic core focus, Jazz Pharmaceuticals went onto to sell its women’s healthcare business to Meda.
Today the company is looking to acquire or in-license late stage commercial products, also mentioned in its partnering strategy is its desire to invest a portion of its sales in lower isk development of speciality pharma products.
Jazz Pharmaceuticals is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.
Events with Jazz Pharmaceuticals presence include but are not limited to:
- BIO International Convention and Business Forum
- BioEurope / BioEurope Spring
- Jefferies Global Healthcare Conference
For a full list of forthcoming partnering events where you could meet with Jazz Pharmaceuticals in person visit Current Partnering’s Event calendar.
Contacting Jazz Pharmaceuticals for partnering
Jazz Pharmaceuticals can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels:
Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.
See Current Partnering’s event calendar for details of forthcoming events.
Direct contact: there are several sources of direct contact with Jazz Pharmaceuticals’ business development team
- Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.
- Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. This page on the Jazz Pharmaceuticals website has details for contacting Jazz Pharmaceuticals.
- LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.
Many of Jazz Pharmaceuticals’ business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Jazz Pharmaceuticals Linkedin Page.
Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the contacts page on the Jazz Pharmaceuticals website for potential partnering opportunities and general contact names.
Available reports from Current Partnering
Report: Partnering Agreements with Jazz Pharmaceuticals 2009-2014
Report: Partnering Deals and Alliances with Big Biotech
Available resources for deal coverage for Jazz Pharmaceuticals
Read: more on Jazz Pharmaceuticals company profile, recent partnering, M&A and financing news and articles
Report: Practical Guide to Finding Partners
View: Current Partnering Insight’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering Insight’s M&A Scorecard – view top life science M&A deals by value
View: Current Partnering Insight’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Partnering Activity – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Partnering Activity – latest trends in big pharma deal making activity
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk